N-succinyl-chitosan as a drug carrier: Water-insoluble and water-soluble conjugates

Biomaterials

Volumn 25, Issue 5, 2004, Pages 907-915

  Kato, Yoshinori ^a,b   Onishi, Hiraku ^a   Machida, Yoshiharu ^a  

^a HOSHI UNIVERSITY   (Japan)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biodistribution; Cancer chemotherapy; Conjugates; Mitomycin C; N succinyl chitosan; Prodrug

Indexed keywords

BIOCOMPATIBILITY; BODY FLUIDS; MACROMOLECULES; ONCOLOGY; SOLUBILITY; TISSUE; TOXICITY;

SYSTEMIC CIRCULATION;

DRUG INFUSION;

ANTINEOPLASTIC AGENT; CHITOSAN DERIVATIVE; N SUCCINYLCHITOSAN; N SUCCINYLCHITOSAN MITOMYCIN C CONJUGATE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BIOCOMPATIBILITY; DEACETYLATION; DRUG EFFICACY; DRUG RELEASE; HALF LIFE TIME; LYMPH NODE; MAXIMUM TOLERATED DOSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE; REVIEW; SOLUBILITY;

MURINAE;

EID: 0242522338     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0142-9612(03)00598-2     Document Type: Review

References (55)

1. Felt O., Buri P., Gurny R. A unique polysaccharide for drug delivery. Drug Dev Ind Pharm. 24:1998;979-993.
2. Illum L. Chitosan and its use of as a pharmaceutical excipient. Pharm Res. 15:1998;1326-1331.
3. Yamaguchi R., Arai Y., Itoh T., Hirano S. Preparation of partially N-succinylated chitosans and their cross-linked gels. Carbohydr Res. 88:1981;172-175.
4. Kato Y., Onishi H., Machida Y. Depolymerization of N-succinyl-chitosan by hydrochloric acid. Carbohydr Res. 337:2002;561-564.
5. Kuroyanagi Y., Shiraishi A., Shirasaki Y., Nakakita N., Yasutomi Y., Takano Y., Shioya N. Development of a new wound dressing with antimicrobial delivery capability. Wound Repair Regen. 2:1994;122-129.
6. Izume M. The application of chitin and chitosan to cosmetics. Chitin Chitosan Res. 4:1998;12-17.
7. Tajima M., Izume M., Fukuhara T., Kimura T., Kuroyanagi Y. Development of new wound dressing composed of N-succinyl chitosan and gelatin. Seitai Zairyo. 18:2000;220-226.
8. Nakagawa A, Myata S, Shimozono J, Soejima Y, Saida M. Water-soluble chitosan or chitin for treatment of arthritis. JP Patent No. 06107551, 1994.
9. Kamiyama K., Onishi H., Machida Y. Biodisposition characteristics of N-succinyl-chitosan and glycol-chitosan in normal and tumor-bearing mice. Biol Pharm Bull. 22:1999;179-186.
10. Kato Y., Onishi H., Machida Y. Evaluation of N-succinyl-chitosan as a systemic long-circulating polymer. Biomaterials. 21:2000;1579-1585.
11. Takakura Y., Takagi A., Hashida M., Sezaki H. Disposition and tumor localization of mitomycin C-dextran conjugates in mice. Pharm Res. 4:1987;293-300.
12. Takakura Y., Fujita T., Hashida M., Sezaki H. Disposition characteristics of macromolecules in tumor-bearing mice. Pharm Res. 7:1990;339-346.
13. Tanaka T., Kaneo Y., Shiramoto S., Iguchi S. The disposition of serum proteins as drug-carriers in mice bearing Sarcoma 180. Biol Pharm Bull. 16:1993;1270-1275.
14. Yamaoka T., Kuroda M., Tabata Y., Ikada Y. Body distribution of dextran derivatives with electric charges after intravenous administration. Int J Pharm. 113:1995;149-157.
15. Kato Y, Onishi H, Machida Y. Lactosaminated N-succinyl-chitosan: preparation and biodistribution into the intestine, bone, lymph nodes and male genital organs after i.v. administration. Macromol Res, in press.
16. Kato Y., Onishi H., Machida Y. Biological fate of highly succinylated N-succinyl-chitosan and antitumor characteristics of its water-soluble conjugate with mitomycin C at i.v. and i.p. administration into tumor-bearing mice. Biol Pharm Bull. 23:2000;1497-1503.
17. Peterson H-.I. Vascular and extraavascular spaces in tumors. tumor vascular permeability Peterson H-.I. Tumor blood circulation: angiogenesis, vascular morphology, and blood flow of experimental and human tumors. 1979;77-85 CRC Press, Boca Raton, FL.
18. Gerlowski L.E., Jain R.K. Microvascular permeability of normal and neoplastic tissues. Microvasc Res. 31:1986;288-305.
19. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy. mechanism of tumoritropic accumulation of proteins and the antitumor agent Smancs Cancer Res. 46:1986;6387-6392.
20. Maeda H., Matsumura Y. Tumoritropic and lymphotropic principles of macromolecular drugs. Crit Rev Ther Drug Carrier Syst. 6:1989;193-210.
21. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics. a review J Control Release. 65:2000;271-284.
22. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature. the key role of tumor-selective macromolecular drug targeting Adv Enzyme Regul. 41:2001;189-207.
23. Kato Y., Onishi H., Machida Y. Biological characteristics of lactosaminated N-succinyl-chitosan as a liver-specific drug carrier in mice. J Control Release. 70:2001;295-307.
24. Kato Y., Onishi H., Machida Y. Lactosaminated and intact N-succinyl-chitosans as drug carriers in liver metastasis. Int J Pharm. 226:2001;93-106.
25. Regoeczi E., Debanne M.T., Hatton M.W.C., Koj A. Elimination of asialofetuin and asialoorosomucoid by the intact rat - quantitative aspects of the hepatic clearance mechanism. Biochim Biophys Acta. 541:1978;372-384.
26. Ashwell G., Harford J. Carbohydrate-specific receptors of the liver. Ann Rev Biochem. 51:1982;531-554.
27. Fiume L., Busi C., Mattioli A., Balboni P.G., Barbanti-Brodana G. Hepatocyte targeting of adenine-9-β-D-arabinofuranoside 5′-monophosphate (ara-AMP) coupled to lactosaminated albumin. FEBS Lett. 129:1981;261-264.
28. Fiume L., Busi C., Mattioli A. Lactosaminated human serum albumin as hepatotropic drug carrier rate of uptake by mouse liver. FEBS Lett. 146:1982;42-46.
29. O'Hare K.B., Hume I.C., Scarlett L., Chytry V., Kopeckova P., Kopecek J., Duncan R. Effect of galactose on interaction of N-(2-hydroxypropyl) methacrylamide copolymers with hepatoma cells in culture. preliminary application to an anticancer agent, daunomycin Hepatology. 10:1989;207-214.
30. Kaneo Y., Tanaka T., Iguchi S. Targeting of mitomycin C to the liver by the use of asialofetuin as a carrier. Chem Pharm Bull. 39:1991;999-1003.
31. 123I-labelled N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugate containing galatosamine following intravenous administration to nude mice bearing hepatic human colon carcinoma. J Drug Targeting. 3:1996;385-390.
32. Hashida M., Hirabayashi H., Nishikawa M., Takakura Y. Targeted delivery of drugs and proteins to the liver via receptor-mediated endocytosis. J Control Release. 46:1997;129-137.
33. Mahato R.I., Takemura S., Akamatsu K., Nishikawa M., Takakura Y., Hashida M. Physicochemical and disposition characteristics of antisense oligonucleotides complexed with glycosylated poly(L-lysine). Biochem Pharmacol. 53:1997;887-895.
34. Akamatsu K., Imai M., Yamasaki Y., Nishikawa M., Takakura Y., Hashida M. Disposition characteristics of glycosylated poly(amino acids) as liver cell-specific drug carrier. J Drug Targeting. 6:1998;229-239.
35. Bridges K., Harford J., Ashwell G., Klausner R.D. Fate of receptor and ligand during endocytosis of asialoglyocoproteins by isolated hepatocytes. Proc Natl Acad Sci USA. 79:1982;350-354.
36. Schwartz A.L., Fridovich S.E., Lodish H.F. Kinetics of internalization and recycling of the asialoglycoprotein receptor in a hepatoma cell line. J Biol Chem. 257:1982;4230-4237.
37. Harford J., Bridges K., Ashwell G., Klausner R.D. Intracellular dissociation of receptor-bound asialoglycoproteins in cultured hepatocytes. J Biol Chem. 258:1983;3191-3197.
38. Kierszenbaum A.L., Rivkin E., Chang P.L., Tres L.L., Olsson C.A. Galactosyl receptor, a cell surface C-type lectin of normal and tumoral prostate epithelial cells with binding affinity to endothelial cells. The Prostate. 43:2000;175-183.
39. Song Y., Onishi H., Nagai T. Conjugate of mitomycin C with N-succinyl-chitosan. in vitro drug release properties, toxicity and antitumor activity Int J Pharm. 98:1993;121-130.
40. Onishi H., Song Y., Ichikawa H., Machida Y., Nagai T. Macromolecular prodrugs of cytarabine and mitomycin C with chitosan, N-succinyl-chitosan and 6-O-carboxymethyl-chitin as drug carriers. Karnicki Z.S., Brzeski M.M., Bykowski P.J., Wojtasz-Pajak A. Chitin World. 1994;301-310 Wirtschaftsverlag NW-Verlag fur neue wissenschaft, Bremerhaven.
41. Shirahata K. Section VI. derivatives and activities Taguchi T. Mitomycin. Basic studies - chapter 1: chemical. 1984;25-43 Kyowa Kikaku Tsushin, Tokyo.
42. Song Y., Onishi H., Machida Y. Synthesis and drug-release characteristics of the conjugates of mitomycin C with N-succinyl-chitosan and carboxymethyl-chitin. Chem Pharm Bull. 40:1992;2822-2825.
43. Sheehan J.C., Hlavka J.J. The use of water-soluble and basic carbodiimides in peptide synthesis. J Org Chem. 21:1956;439-441.
44. Song Y., Onishi H., Machida Y., Nagai T. Particle characteristics of carboxymethyl-chitin-mitomycin C conjugate and N-succinyl-chitosan-mitomycin C conjugate and their distribution and histological effect on some tissues after intravenous administration. STP Pharm Sci. 5:1995;162-170.
45. Onishi H., Takahashi H., Yoshiyasu M., Machida Y. Preparation and in vitro properties of N-succinyl-chitosan- or carboxymethylchitin-mitomycin C conjugate microparticles with specified size. Drug Dev Ind Pharm. 27:2001;659-667.
46. Onishi H., Nagai T., Machida Y. Application of chitin, chitosan, and their derivatives to drug carriers for microparticulated or conjugated drug delivery systems. Goosen M.F.A. Applications of chitin and chitosan. Part IV: medicine and biotechnology. 1997;205-231 Technomic Publishing Co, Lancaster.
47. Song Y., Onishi H., Machida Y., Nagai T. Drug release and antitumor characteristics of N-succinyl-chitosan-mitomycin C as an implant. J Control Release. 42:1996;93-100.
48. Sato M., Onishi H., Kitano M., Machida Y., Nagai T. Preparation and drug release characteristics of the conjugates of mitomycin C with glycol-chitosan and N-succinyl-chitosan. Biol Pharm Bull. 19:1996;241-245.
49. Kato Y., Onishi H., Machida Y. A novel water-soluble N-succinyl-chitosan- mitomycin C conjugate prepared by direct carbodiimide coupling. physicochemical properties, antitumor characteristics and systemic retention STP Pharm Sci. 10:2000;133-142.
50. Song Y., Onishi H., Nagai T. Pharmacokinetic characteristics and antitumor activity of the N-succinyl-chitosan-mitomycin C conjugate and the carboxymethyl-chitin-mitomycin C conjugate. Biol Pharm Bull. 16:1993;48-54.
51. Sato M., Onishi H., Takahara J., Machida Y., Nagai T. In vivo drug release and antitumor characteristics of water-soluble conjugates of mitomycin C with glycol-chitosan and N-succinyl-chitosan. Biol Pharm Bull. 19:1996;1170-1177.
52. Kato Y., Onishi H., Machida Y. Efficacy of lactosaminated and intact N-succinyl-chitosan-mitomycin C conjugates against M5076 liver metastatic cancer. J Pharm Pharmacol. 54:2002;529-537.
53. Kato Y., Onishi H., Machida Y. Tumor cell uptake of lactosaminated and intact N-succinyl-chitosans and antitumour effects of conjugates with mitomycin C. Anticancer Res. 22:2002;2771-2776.
54. Hashida M., Kato A., Kojima T., Muranishi S., Sezaki H., Tanigawa N., Satomura K., Hikasa Y. Antitumor activity of mitomycin C-dextran conjugate against various murine tumors. Gann. 72:1981;226-234.
55. Kato A., Takakura Y., Hashida M., Kimura T., Sezaki H. Physico-chemical and antitumor characteristics of high molecular weight prodrugs of mitomycin C. Chem Pharm Bull. 30:1982;2951-2957.